Author

C. E. Bowman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Organism:human· 2 Research Focus:metabolism & bioenergetics· 2 Assay:metabolomics· 2

Frequent Co-Authors

Z. Arany· 4 shared C. Jang· 2 shared J. Patel· 2 shared A. K. Rustgi· 1 shared B. Kim· 1 shared C. M. Simon· 1 shared D. P. Kelly· 1 shared E. Fernandez Garcia· 1 shared

Activity by Year

2023-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Z. Arany

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

HIF2α inhibits glutaminase clustering in mitochondria to sustain growth of clear cell Renal Cell Carcinoma

W. Zhao, B. Kim, N. J. Coffey, S. Bowers, Y. Jiang, C. E. Bowman, M. Noji, C. Jang, C. M. Simon, Z. Arany, B. Kim

This study shows HIF2α prevents GLS1 clustering in mitochondria, protecting ccRCC cells from glutamine deprivation, and suggests targeting GLS1 clustering could enhance HIF2 therapy.

bioRxiv · May 4, 2024Cancer Biology

Sodium-glucose co-transporter 2 Inhibitors Act Independently of SGLT2 to Confer Benefit for Heart Failure with Reduced Ejection Fraction in Mice

J. H. Berger, T. R. Matsuura, C. E. Bowman, R. Taing, J. Patel, L. Lai, T. C. Leone, J. D. Reagan, S. M. Haldar, Z. Arany, D. P. Kelly

This study shows that SGLT2 inhibitors improve heart failure in mice independently of their metabolic effects, even when SGLT2 is absent.

bioRxiv · Apr 29, 2024Physiology

Off-target depletion of plasma tryptophan by allosteric inhibitors of BCKDK

C. E. Bowman, M. D. Neinast, C. Jang, J. Patel, M. C. Blair, E. T. Mirek, W. O. Jonsson, Q. Chu, L. Merlo, L. Mandik-Nayak, T. G. Anthony, J. D. Rabinowitz, Z. Arany

This study shows that BT2, an inhibitor of BCKDK, reduces plasma tryptophan by displacing it from albumin, revealing an off-target effect on tryptophan metabolism.

bioRxiv · Mar 5, 2024Pharmacology & Toxicology

The mitochondrial Ca2+ channel MCU is critical for tumor growth by supporting cell cycle progression and proliferation

E. Fernandez Garcia, U. Paudel, M. C. Noji, C. E. Bowman, J. R. Pitarresi, A. K. Rustgi, K. E. Wellen, Z. Arany, J. S. Weissenrieder, J. K. Foskett

This study shows that the mitochondrial Ca2+ channel MCU supports tumor growth by enabling cell cycle progression and proliferation through mitochondrial Ca2+ uptake, despite unchanged mitochondrial function.

bioRxiv · Apr 26, 2023 · PreprintCancer Biology